p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma

BACKGROUND: Lung cancer is still the main cause of cancer death worldwide despite the availability of targeted therapies and immune-checkpoint inhibitors combined with chemotherapy. Cancer cell heterogeneity and primary or acquired resistance mechanisms cause the elusive behaviour of this cancer and...

Descripción completa

Detalles Bibliográficos
Autores principales: Giordano, Federica, Vaira, Valentina, Cortinovis, Diego, Bonomo, Sara, Goedmakers, Joyce, Brena, Federica, Cialdella, Annamaria, Ianzano, Leonarda, Forno, Irene, Cerrito, Maria Grazia, Giovannoni, Roberto, Ferri, Gian Luca, Tasciotti, Ennio, Vicent, Silve, Damarco, Francesco, Bosari, Silvano, Lavitrano, Marialuisa, Grassilli, Emanuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570906/
https://www.ncbi.nlm.nih.gov/pubmed/31200752
http://dx.doi.org/10.1186/s13046-019-1199-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6570906/
https://www.ncbi.nlm.nih.gov/pubmed/31200752
http://dx.doi.org/10.1186/s13046-019-1199-7

Ejemplares similares